|
Pronunciation |
|
(POE
lee oh VYE rus vak SEEN, live,
try VAY lent, OR al) |
|
|
U.S. Brand
Names |
|
Orimune® |
|
|
Generic
Available |
|
No |
|
|
Synonyms |
|
OPV; Sabin Vaccine; TOPV |
|
|
Pharmacological Index |
|
Vaccine |
|
|
Use |
|
Poliovirus immunization |
|
|
Pregnancy Risk
Factor |
|
C |
|
|
Adverse
Reactions |
|
All serious adverse reactions must be reported to the Vaccine Adverse Event
Reporting System (1-800-822-7967) |
|
|
Stability |
|
Keep in freezer; vaccine must remain frozen to retain
potency |
|
|
Usual Dosage |
|
Oral:
Older Children, Adolescents, and Adults: Two 0.5 mL doses 8 weeks apart;
third dose of 0.5 mL 6-12 months after second dose; a reinforcing dose of 0.5 mL
should be given before entry to school, in children who received the third
primary dose before their fourth birthday |
|
|
Dental Health: Local
Anesthetic/Vasoconstrictor
Precautions |
|
No information available to require special precautions |
|
|
Dental Health:
Effects on Dental Treatment |
|
No effects or complications reported |
|
|
Patient
Information |
|
Because of the risk of vaccine-associated paralysis, unvaccinated family
members and close personal contacts should be vaccinated prior to the
child |
|
|
Nursing
Implications |
|
Do not administer parenterally; administer directly or dilute with distilled
water, simple syrup USP, or milk; may be administered on bread or sugar
cubes |
|
|
Dosage Forms |
|
Solution, oral: Mixture of type 1, 2, and 3 viruses in monkey kidney tissue
(0.5 mL) |
|
Copyright © 1978-2000 Lexi-Comp Inc. All Rights Reserved
|